Metastatic Triple-negative Breast Cancer Clinical Trial
Official title:
A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04986852 -
Olinvacimab With Pembrolizumab in Patients With mTNBC
|
Phase 2 | |
| Recruiting |
NCT05831553 -
TIP in Patients Affected by Metastatic TNBC
|
||
| Recruiting |
NCT05570253 -
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04454437 -
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
|
Phase 2 | |
| Recruiting |
NCT05101096 -
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Suspended |
NCT04250818 -
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
|
||
| Completed |
NCT03004183 -
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
|
Phase 2 | |
| Recruiting |
NCT06027268 -
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05746728 -
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05089643 -
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
|
Phase 2 |